

# BMJ Open A systematic analysis of UK cancer research funding by gender of primary investigator

Charlie D Zhou,<sup>1</sup> Michael G Head,<sup>2</sup> Dominic C Marshall,<sup>3</sup> Barnabas J Gilbert,<sup>4</sup> Majd A El-Harasis,<sup>5</sup> Rosalind Raine,<sup>6</sup> Henrietta O'Connor,<sup>7</sup> Rifat Atun,<sup>8</sup> Mahiben Maruthappu<sup>9</sup>

**To cite:** Zhou CD, Head MG, Marshall DC, *et al*. A systematic analysis of UK cancer research funding by gender of primary investigator. *BMJ Open* 2018;**8**:e018625. doi:10.1136/bmjopen-2017-018625

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-018625>).

RA and MM contributed equally.

RA and MM are Joint senior authors.

Received 10 July 2017

Revised 26 October 2017

Accepted 3 November 2017



For numbered affiliations see end of article.

## Correspondence to

Charlie D Zhou;  
chazhou@gmail.com

## ABSTRACT

**Objectives** To categorically describe cancer research funding in the UK by gender of primary investigator (PIs).

**Design** Systematic analysis of all open-access data.

**Methods** Data about public and philanthropic cancer research funding awarded to UK institutions between 2000 and 2013 were obtained from several sources. Fold differences were used to compare total investment, award number, mean and median award value between male and female PIs. Mann-Whitney U tests were performed to determine statistically significant associations between PI gender and median grant value.

**Results** Of the studies included in our analysis, 2890 (69%) grants with a total value of £1.82 billion (78%) were awarded to male PIs compared with 1296 (31%) grants with a total value of £512 million (22%) awarded to female PIs. Male PIs received 1.3 times the median award value of their female counterparts ( $P<0.001$ ). These apparent absolute and relative differences largely persisted regardless of subanalyses.

**Conclusions** We demonstrate substantial differences in cancer research investment awarded by gender. Female PIs clearly and consistently receive less funding than their male counterparts in terms of total investment, the number of funded awards, mean funding awarded and median funding awarded.

## INTRODUCTION

Within the European Union (EU), women represent nearly half of the workforce and more than half of all university graduates; however, they are under-represented in senior positions in the workplace.<sup>1</sup> In science, research and development, the attrition rate among women exceeds that of their male counterparts at every stage of career progression in a phenomenon termed the ‘leaky pipeline’, with women representing 46% of PhD graduates, 33% of career scientists and 22% of grade A researchers (the highest posts at which research is conducted—equivalent to professorships in the UK).<sup>2</sup> In the field of medical science, women represent 17.8% of grade A researchers.<sup>2</sup> This problem is not

## Strengths and limitations of this study

- This is the first study to present detailed quantifiable differences in cancer research funding between male and female primary investigators in the UK.
- Our study is dependent on the accuracy of original investment data from the funding bodies.
- We could not openly access data of private sector research funding, nor were we able to obtain disaggregated data from Cancer Research UK.
- While the gender discrepancies in cancer research funding observed in our study period are likely multifactorial, this study does not allow us to postulate any potential underlying mechanisms responsible for these observations.

limited to the EU, and several studies have similarly explored the gender imbalance in the USA.<sup>3–5</sup> Indeed data collected by Unesco suggest that just one in five countries worldwide has achieved gender parity in scientific research (defined as when 45% to 55% of researchers are women).<sup>6</sup> Previous studies have proposed a number of factors that may contribute towards this observed ‘leaky pipeline’ including societally defined traditional gender roles, attitudes towards career deviation and career breaks, lack of mentorship, institutional discrimination and sexual harassment.<sup>7</sup>

This problem is an ongoing concern both to policy-makers and to the science community at large, particularly within the science, technology, engineering, maths and medicine (STEMM) fields.<sup>8</sup> A number of initiatives have sought to highlight and promote change in order to address this issue. Gender equality is a central component of Horizon 2020, a flagship initiative to secure Europe’s global competitiveness.<sup>9</sup> Whereas previous campaigns<sup>10 11</sup> have had unclear impact and in some instances been described as offensive to gender equality,<sup>12</sup> this will be one of the first

efforts to be legally enshrine gender equality into research and innovation.<sup>9</sup> Three central objectives of Horizon 2020 include fostering gender balance in research teams, ensuring gender balance in decision-making panels and groups as well as integrating gender analysis in research and innovation content.

With regard to science research funding, men receive a 4.4% higher funding application success rate compared with women in the EU (31.8% success rate for men, 27.4% success rate for women).<sup>13</sup> Previous research has shown that in general, it is harder for women to obtain high prestige awards and that female applicants have proportionately more success when applying for smaller grants.<sup>14</sup>

In the biomedical sciences, women receive smaller grants compared with their male counterparts both in the USA<sup>15</sup> and the UK.<sup>16</sup> Women are noticeably under-represented in UK clinical oncology research<sup>17</sup> and gender discrepancies exist in the success rates of grant applications to UK funders.<sup>18</sup> Subconscious bias has been demonstrated in the decision-making of academic science recruiters<sup>19</sup> and also reported by those who assess grant applications.<sup>18</sup> Although gender discrepancies do appear to vary across specific fields of research, it has been previously reported that women do not appear overtly disadvantaged in social science research.<sup>20</sup>

Our group has previously undertaken a systematic comparison of infectious disease research funding by gender within the UK, showing clear and consistent differences between the genders in total funding and median award size, across a range of diseases and types of science.<sup>21</sup> Here we examine the distribution of cancer research funding awarded to men and women primary investigators (PIs) across specific cancers, funder categories and along the research and development (R&D) continuum.

## MATERIALS AND METHODS

Our methods build on those developed for previous analyses of infectious disease research investments, which are described in detail elsewhere,<sup>22–24</sup> and adapted in subsequent peer-reviewed publications ([www.researchinvestments.org/publications](http://www.researchinvestments.org/publications)).

We systematically examined funding awards from a number of public and philanthropic cancer research funding bodies (including the Medical Research Council, Department of Health, Biotechnology and Biological Sciences Research Council, Engineering and Physical Science Research Council, Wellcome Trust, European Commission, as well as nine members of the Association of Medical Research Charities) between 2000 and 2013. Information was obtained by downloading openly accessible information on the funder website, contacting the funder to request information or searching existing funding databases. For each award, the title and abstract, where available, were individually screened for relevance to cancer research. We excluded awards that were (1) not

obviously or immediately relevant to oncology; (2) led by a non-UK institution; (3) not considered to be for R&D activity. Studies that were completed without funding were also excluded. Private sector data were not available to evaluate at the same level of detail as public and philanthropic research award data and were therefore excluded from this analysis. Cancer Research UK (CRUK) would not provide their funding data at individual award level and so could not be included in the main analysis.

We assigned each study to one of 16 primary cancer site categories and also as many of 14 cross-cutting categories as appropriate. To reduce the impact of skew due to small sample size, we restricted our cancer site analysis to those site-specific cancers with at least 15 studies across both sexes. As a result, testicular (14 studies), bone (13 studies), bladder (10 studies), thyroid (4 studies) and cholangiocarcinoma (2 studies) were excluded from our site-specific cancer analysis.

The 14 cross-cutting categories were paediatric, geriatric, infection-associated, women's health, men's health, occupational health, pathogenesis, diagnostic/screening/monitoring, drug therapy, radiotherapy, surgery, immunology, psychosocial and global health. The 'other' category was only used when none of the aforementioned categories were deemed to be appropriate. We allocated studies to one of five categories along the R&D continuum: preclinical; phase I, II or III clinical trials; product development (including phase IV activity); public health; and cross-disciplinary research. Cross-disciplinary awards were defined as studies that clearly considered research across two or more different types of science (eg, preclinical science leading into a phase I trial).

Where the PI was named as the recipient of an award, the PIs were categorised as male or female. Where there was any uncertainty as to gender there was further scrutiny via review of the literature, institutional websites or publicly available publications and documents. Where we were finally unable to identify a PI's gender, the study was assigned as 'unclear'. Where the recipient PI of an award was not identified, the study was assigned as 'unspecified'.

Where awards were described in currencies other than UK pounds, these were converted to UK pounds using the mean exchange rate in the year of the award. All included awards were adjusted for inflation and reported in 2013 UK pounds.

We report descriptive statistics including median, IQR and percentages for categorical variables. Data were graphically inspected for normality using histograms. Mann-Whitney U tests were performed to test for univariate associations between gender and funding. Data were collated in Microsoft Excel 2010 and statistical analysis was performed using R studio (V.0.99.903) and Stata (V.13).

## RESULTS

In our analysis of cancer research investment awarded by public and philanthropic funding bodies to UK institutions

between 2000 and 2014, we identified 4299 funded studies suitable for inclusion. These studies represented a sum total monetary investment of almost £2.4 billion. Of these, 53 studies (1.2%, total investment of £33.2 million) did not specify PI name or gender, while we were unable to ascertain the gender of the named PI for a further 60 studies (1.4%, total investment of £21.8 million). Therefore, 4186 awards, totalling £2.33 billion, were included in our final gender analysis (table 1, figures 1 and 2).

There were 2890 grants (69%) with a total value of £1.82 billion (78%) awarded to male PIs, while female PIs received 1296 grants (31%) with a total value of £512 million (22%). The median grant value was greater for men (£252 647; IQR: £127 343–£553 560) than for women (£198 485; IQR: £99 317–£382 650). Men received statistically significant larger grants in terms of median value compared with women ( $P<0.001$ ). Similarly, mean grant value was greater for men (£630 324; SD £1 662 559) than for women (£394 730; SD: £666 574). Across all cancer research funding grants awarded, male PIs received 3.6 times the sum investment value, 1.6 times the mean award value and 1.3 times the median award values compared with their female counterparts.

There was a statistically significant difference between the genders in median grant value for research funding in three specific cancer sites. Men received 2.9 times the funding of women PIs in cervical cancer ( $P<0.001$ ). Women received 2.4 and 2.0 times the funding of men in liver cancer ( $P<0.05$ ) and mesothelioma ( $P<0.01$ ), respectively. The differences in median funding for all other cancer sites were not statistically significant.

Some of the greatest apparent gender discrepancies in cancer funding by site are observed in awards for sex-specific cancers. For prostate cancer, male PIs receive 13.8, 3.5 and 2.0 times the investment of their female counterparts in total, mean and median funding, respectively. In cervical cancer research, men receive 9.9, 6.6 and 2.9 times the funding of women PIs in total, mean and median funding, respectively. In ovarian cancer research, there was a 4.6-fold, 5.7-fold and 1.2-fold difference between men and women in total, mean and median funding, respectively. And similarly in breast cancer, there was a 1.6-fold, 1.1-fold and 1.4-fold difference between men and women in total, mean and median funding, respectively.

Men received more total investment than women across all disease themes. A statistically significant difference in median grant value between the genders was present for 6 of the 14 disease themes included in our analysis. Men received greater median funding in all six of these disease themes: pathogenesis (1.2-fold difference,  $P<0.001$ ); drug therapy (1.3-fold difference,  $P<0.001$ ); diagnostic, screening and monitoring (1.6-fold difference,  $P<0.001$ ); psychosocial (2.7-fold difference,  $P<0.01$ ); men's health (2.1-fold difference,  $P<0.05$ ); and surgery (2.1-fold difference,  $P<0.05$ ).

In keeping with our findings in our site-specific analysis, there was a consistent trend of increased funding for

male PIs in sex-specific cancer research. In men's health, there was a 14.1-fold, 3.7-fold and 2.7-fold difference in favour of male PIs in terms of total, mean and median investment, respectively. In women's health, there was a 1.9-fold, 1.4-fold and 1.3-fold difference in favour of male PIs in total, mean and median investment, respectively.

Male PIs receive statistically significant greater median funding than women at all points of the R&D pipeline: preclinical (1.2-fold difference,  $P<0.001$ ); phase I, II, or III clinical trials (1.9-fold difference,  $P<0.001$ ); product development research (1.5-fold difference,  $P<0.01$ ); cross-disciplinary research (1.2-fold difference,  $P<0.01$ ); and public health (1.5-fold difference,  $P<0.001$ ).

With the exception of the Biotechnology and Biological Sciences Research Council, all funding organisations on average awarded larger median awards to men than to women. These differences were statistically significant for four funding bodies: Medical Research Council (1.4-fold difference,  $P<0.001$ ), charities—excluding Wellcome Trust (1.2-fold difference,  $P<0.001$ ), Department of Health (1.6-fold difference,  $P<0.001$ ) and Wellcome Trust (1.3-fold difference,  $P<0.05$ ).

## DISCUSSION

In this first quantifiable systematic comparison of UK cancer research investment by PI gender for the period 2000–2013, we demonstrate that female PIs clearly and consistently receive less funding than their male counterparts in terms of total investment, the number of funded awards, mean funding awarded and median funding awarded. This apparent absolute and relative discrepancy in funding largely persisted regardless of analysis by cancer site, disease theme, research and development pipeline, or by funder.

Our study is a purely descriptive analysis which does not and cannot assess any potential explanatory mechanism that might underlie our observed gender discrepancy in cancer research funding. It cannot for example account for any potential influence of conscious or subconscious gender bias in cancer research funding decisions, and there is no evidence here of any bias on the part of funding bodies. We would caution against drawing conclusions regarding factors that may influence our reported observations from this study alone. Instead, we would advocate that these results be interpreted within the context of the existing scientific body of evidence on the topic. Nevertheless, this study provides further evidence into the apparent funding gap between the sexes in biomedical research.<sup>15 16 21</sup>

The attrition rate among women exceeds that of their male counterparts at every stage of scientific career progression.<sup>2</sup> Existing data show that women are under-represented at the highest research posts in the UK, accounting for 23.2% of professors as of 2010,<sup>13</sup> who would likely represent the great majority of PIs, particularly in larger awards. The lack of information on seniority and track record of funding applicants is an important

**Table 1** Gender-specific UK cancer research funding by cancer site, disease theme, phase of research and development pipeline and by funding organisation

| Cancer site                            | Male PIs     |                   |                       |                             | Female PIs   |                   |                       |                               | Fold difference |            |              |
|--|--------------|-------------------|-----------------------|-----------------------------|--------------|-------------------|-----------------------|-------------------------------|-----------------|------------|--------------|
|  | Award number | Sum investment, £ | Mean award (SD); £    | Median award (IQR); £       | Award number | Sum investment, £ | Mean award (SD); £    | Median award (IQR); £         | Sum investment  | Mean award | Median award |
|  |              |                   |                       |                             |              |                   |                       |                               |                 |            |              |
| All                                    | 2890         | 1 821 637 149     | 630 324 (1 662 559)   | 252 647 (127 343–563 560)   | 1296         | 511 570 050       | 394 730 (666 574)     | 198 485 (99 317–382 650)      | 3.6             | 1.6        | 1.3***       |
| Head and neck                          | 16           | 17 490 769        | 1 093 173 (1 046 928) | 637 418 (260 926–2 242 703) | 4            | 7 599 863         | 189 965 (148 630)     | 183 250 (61 937–317 994)      | 23.0            | 5.8        | 3.5          |
| Cervical                               | 15           | 12 678 187        | 845 212 (1 070 241)   | 353 754 (94 896–1 574 367)  | 10           | 1 281 813         | 128 181 (96 538)      | 123 623 (30 732–206 392)      | 9.9             | 6.6        | 2.9**        |
| Prostate                               | 71           | 125 769 548       | 1 771 402 (6 980 741) | 377 700 (190 072–893 840)   | 18           | 9 090 234         | 505 013 (740 863)     | 188 950 (103 103–360 595)     | 13.8            | 3.5        | 2.0          |
| Colorectal                             | 93           | 57 301 015        | 616 139 (750 261)     | 287 749 (112 437–893 840)   | 46           | 18 296 468        | 397 749 (522 529)     | 176 320 (73 736–404 692)      | 3.1             | 1.6        | 1.6          |
| Breast                                 | 325          | 82 761 091        | 254 649 (420 671)     | 166 321 (538 32–212 298)    | 235          | 52 971 924        | 225 412 (414 352)     | 122 721 (22 583–220 325)      | 1.6             | 1.1        | 1.4          |
| Upper gastrointestinal and oesophageal | 23           | 12 946 692        | 562 900 (650 867)     | 274 268 (103 500–918 058)   | 13           | 8 736 139         | 672 011 (1 659 329)   | 190 546 (75 424–240 704)      | 1.5             | 0.8        | 1.4          |
| Lung                                   | 42           | 17 589 619        | 418 800 (740 402)     | 159 766 (88 544–284 718)    | 35           | 5 712 151         | 163 204 (192 192)     | 127 698 (57 173–174 667)      | 3.1             | 2.6        | 1.3          |
| Ovarian                                | 21           | 36 259 818        | 1 812 991 (5 165 397) | 266 344 (147 327–1 214 534) | 25           | 7 974 217         | 318 968 (372 325)     | 224 595 (119 951–276 184)     | 4.5             | 5.7        | 1.2          |
| Brain                                  | 9            | 3 223 573         | 358 174 (170 479)     | 406 122 (215 197–503 831)   | 12           | 6 667 742         | 555 645 (651 240)     | 346 106 (162 573–702 297)     | 0.5             | 0.6        | 1.2          |
| Haematological                         | 791          | 263 742 072       | 333 428 (446 336)     | 191 200 (122 138–279 643)   | 360          | 112 494 439       | 312 484 (530 741)     | 180 981 (112 896–250 059)     | 2.3             | 1.1        | 1.1          |
| Skin                                   | 44           | 14 797 603        | 336 309 (562 447)     | 89 456 (70 635–345 581)     | 42           | 7 305 773         | 173 947 (292 287)     | 85 375 (68 113–215 519)       | 2.0             | 1.9        | 1.0          |
| Renal                                  | 11           | 7 727 390         | 702 490 (675 521)     | 296 803 (90 509–1 270 928)  | 8            | 6 158 106         | 769 763 (727 809)     | 542 768 (347 399–822 950)     | 1.3             | 0.9        | 0.6          |
| Mesothelioma                           | 17           | 2 267 977         | 133 410 (117 199)     | 104 084 (65 607–174 656)    | 10           | 2 013 884         | 201 388 (49 059)      | 202 921 (165 605–248 573)     | 1.1             | 0.7        | 0.5**        |
| Liver                                  | 24           | 11 279 988        | 469 999 (516 869)     | 250 892 (138 579–687 402)   | 12           | 13 515 306        | 1 126 276 (1 207 998) | 598 732 (240 881–1 679 106)   | 0.8             | 0.4        | 0.4*         |
| Pancreatic                             | 9            | 4 566 168         | 507 352 (568 171)     | 260 473 (150 980–650 203)   | 5            | 3 685 298         | 737 059 (461 259)     | 1 033 948 (236 145–1 033 948) | 1.2             | 0.7        | 0.3          |
| Disease theme                          |              |                   |                       |                             |              |                   |                       |                               |                 |            |              |
| Psychosocial                           | 43           | 11 524 430        | 268 010 (422 656)     | 164 422 (43 523–274 442)    | 66           | 9 057 598         | 137 236 (251 616)     | 59 994 (20 803–209 699)       | 1.3             | 2.0        | 2.7**        |
| Men's health                           | 84           | 133 173 641       | 1 585 400 (6 430 067) | 364 401 (186 031–855 034)   | 22           | 9 429 269         | 428 603 (687 483)     | 174 513 (87 844–318 514)      | 14.1            | 3.7        | 2.1*         |
| Surgery                                | 54           | 33 398 798        | 618 496 (722 494)     | 272 279 (109 099–877 969)   | 14           | 3 723 997         | 265 999 (538 442)     | 131 481 (20 000–243 687)      | 9.0             | 2.3        | 2.1*         |

Continued

**Table 1** Continued

|                                      | Male PIs     |                   |                       | Female PIs                  |              |                   | Fold difference    |                           |                |            |              |
|--------------------------------------|--------------|-------------------|-----------------------|-----------------------------|--------------|-------------------|--------------------|---------------------------|----------------|------------|--------------|
|                                      | Award number | Sum investment, £ | Mean award (SD); £    | Median award (IQR); £       | Award number | Sum investment, £ | Mean award (SD); £ | Median award (IQR); £     | Sum investment | Mean award | Median award |
| Diagnostic, screening and monitoring | 454          | 277 375 628       | 610 959 (1 353 526)   | 248 793 (109 256–638 341)   | 201          | 71 024 311        | 353 354 (509 792)  | 155 330 (75 224–294 584)  | 3.9            | 1.7        | 1.6***       |
| Radiotherapy                         | 89           | 82 782 734        | 930 143 (2 689 204)   | 283 654 (130 224–445 594)   | 19           | 5 123 806         | 269 674 (265 442)  | 202 125 (68 219–357 426)  | 16.2           | 3.5        | 1.4          |
| Drug therapy                         | 736          | 488 185 281       | 663 295 (2 265 942)   | 221 228 (116 730–553 560)   | 336          | 111 111 295       | 330 688 (510 148)  | 175 374 (79 949–253 435)  | 4.4            | 2.0        | 1.3***       |
| Women's health                       | 361          | 129 487 265       | 358 690 (1 320 959)   | 168 523 (64 649–222 843)    | 265          | 67 078 971        | 253 128 (487 672)  | 131 248 (22 790–230 625)  | 1.9            | 1.4        | 1.3          |
| Immunology (inc biologics)           | 304          | 141 667 662       | 466 012 (885 702)     | 244 741 (130 741–483 283)   | 143          | 50 385 497        | 352 346 (383 905)  | 206 604 (117 699–437 074) | 2.8            | 1.3        | 1.2          |
| Pathogenesis                         | 1714         | 999 693 849       | 583 252 (1 032 142)   | 269 893 (141 355–538 430)   | 775          | 355 962 017       | 459 305 (765 925)  | 225 586 (123 782–448 560) | 2.8            | 1.3        | 1.2***       |
| Paediatrics                          | 115          | 37 509 650        | 326 170 (465 935)     | 179 839 (81 614–310 647)    | 57           | 23 804 132        | 417 616 (693 945)  | 182 305 (113 785–318 681) | 1.6            | 0.8        | 1.0          |
| Infection-associated                 | 87           | 36 098 390        | 414 924 (821 771)     | 221 742 (131 430–436 959)   | 40           | 18 326 629        | 458 165 (706 563)  | 244 555 (140 757–481 060) | 2.0            | 0.9        | 0.9          |
| Global health                        | 7            | 5 003 769         | 714 824 (1 421 938)   | 105 132 (58 229–540 990)    | 5            | 1 431 191         | 286 238 (308 533)  | 154 344 (98 699–377 559)  | 3.5            | 2.5        | 0.7          |
| Geriatrics                           | 3            | 921 777           | 307 259 (409 655)     | 100 259 (42 410–779 108)    | 4            | 694 617           | 173 654 (88 857)   | 178 014 (99 022–248 286)  | 1.3            | 1.8        | 0.6          |
| Occupational health                  | 14           | 1 993 492         | 142 392 (128 096)     | 123 659 (25 355–198 248)    | 3            | 549 492           | 183 164 (34 345)   | 199 998 (143 649–205 845) | 3.6            | 0.8        | 0.6          |
| Phase of research and development    |              |                   |                       |                             |              |                   |                    |                           |                |            |              |
| Phase I–III                          | 182          | 175 953 897       | 966 779 (4 287 134)   | 217 248 (101 493–700 972)   | 109          | 38 598 339        | 354 113 (608 791)  | 117 699 (66 500–236 145)  | 4.6            | 2.7        | 1.9***       |
| Product development                  | 106          | 86 729 963        | 818 207 (2 787 935)   | 230 722 (109 099–515 754)   | 54           | 14 765 649        | 273 437 (407 013)  | 150 469 (39 528–251 035)  | 5.9            | 3.0        | 1.5**        |
| Public health                        | 304          | 162 533 528       | 534 649 (882 173)     | 236 768 (91 284–484 162)    | 181          | 68 169 795        | 376 628 (886 999)  | 160 196 (59 973–273 731)  | 2.4            | 1.4        | 1.5***       |
| Cross-disciplinary                   | 285          | 237 828 497       | 834 486 (1 879 331)   | 274 442 (136 009–806 082)   | 146          | 74 822 967        | 512 486 (791 038)  | 223 617 (105 842–448 477) | 3.2            | 1.6        | 1.2**        |
| Preclinical                          | 1996         | 1 154 505 166     | 578 409 (1 131 681)   | 256 606 (140 073–528 959)   | 802          | 315 115 408       | 392 912 (602 354)  | 214 876 (121 572–435 243) | 3.7            | 1.5        | 1.2***       |
| Funding organisation                 |              |                   |                       |                             |              |                   |                    |                           |                |            |              |
| Department of Health                 | 337          | 326 868 815       | 969 937 (3 477 639)   | 273 251 (109 256–858 065)   | 209          | 71 189 261        | 340 618 (513 879)  | 175 000 (75 424–281 131)  | 4.6            | 2.8        | 1.6***       |
| MRC                                  | 505          | 640 884 752       | 1 269 079 (2 052 363) | 592 592 (351 917–1 348 289) | 253          | 188 994 003       | 747 011 (943 859)  | 434 495 (254 487–748 000) | 3.4            | 1.7        | 1.4***       |
| Wellcome                             | 121          | 116 858 787       | 965 775 (2 035 860)   | 250 809 (165 274–689 373)   | 70           | 23 266 670        | 332 381 (609 652)  | 194 697 (154 344–266 487) | 5.0            | 2.9        | 1.3*         |

Continued

Table 1 Continued

|                                       | Male PIs     |                   |                     | Female PIs                      |              |                   | Fold difference     |                                 |                |            |              |
|---------------------------------------|--------------|-------------------|---------------------|---------------------------------|--------------|-------------------|---------------------|---------------------------------|----------------|------------|--------------|
|                                       | Award number | Sum investment, £ | Mean award (SD); £  | Median award (IQR); £           | Award number | Sum investment, £ | Mean award (SD); £  | Median award (IQR); £           | Sum investment | Mean award | Median award |
| Charity (excluding Wellcome and CRUK) | 1101         | 281 584 160       | 255753 (372 649)    | 163214 (90000–230289)           | 585          | 130 457 245       | 223003 (427 557)    | 137865 (67 135–206068)          | 2.2            | 1.1        | 1.2***       |
| EPSRC                                 | 292          | 163 856 870       | 561153 (939 912)    | 319486 (147 583–605290)         | 63           | 37 693 709        | 598312 (1 126 384)  | 258057 (114605–600998)          | 4.3            | 0.9        | 1.2          |
| BBSRC                                 | 416          | 186 189 724       | 447571 (410 166)    | 373556 (268819–509467)          | 88           | 35 754 106        | 406296 (277 730)    | 385328 (290714–480990)          | 5.2            | 1.1        | 1.0          |
| European Commission (inc ERC)         | 36           | 56 188 966        | 1 560 805 (426 113) | 1 414 393 (1 261 751–1 768 211) | 9            | 14 693 323        | 1 632 591 (395 550) | 1 383 393 (1 361 130–2 063 706) | 3.8            | 1.0        | 1.0          |
| Other                                 | 82           | 49 205 075        | 600061 (2 096 627)  | 144907 (92673–268658)           | 19           | 9 521 733         | 501143 (773 838)    | 50403 (25092–1 013 231)         | 5.2            | 1.2        | 2.9          |

Cancer sites with fewer than 15 total awards are not presented in this table.

We were unable to identify the phase of research and development for 26 studies.

\*P<0.05, \*\*P<0.01, \*\*\*P<0.001.


BBSRC, Biotechnology and Biological Sciences Research Council; CRUK, Cancer Research UK; EPSRC, Engineering and Physical Science Research Council; ERC, European Research Council; MRC, Medical Research Council; PI, primary investigator.

gap in this study and precludes the conclusion that gender bias is responsible for the observed differences in cancer research funding. Indeed, if gender equality were to be achieved in medical science, a generational lag effect may be expected before this was reflected in funding data.

However, there is mounting evidence to suggest that the existing gender imbalances in researcher numbers do not wholly explain the observable gender gap in funding. At all stages of career progression, female scientists tend to experience lower success rates compared with male scientists when applying for research funding.<sup>25–27</sup> Even when success rates are equal, female scientists tend to receive less in terms of award value.<sup>16 28</sup> This is reflected by internal annual reports by Research Councils UK which represents a strategic partnership between seven of the UK research councils, awards from three of which have been included in our analysis. Female researchers made up 24% of standard grant applications (shorter in duration than 4 years or less than £1 million in value) and experienced a success rate of 25% compared with 29% among male applicants.<sup>29</sup> This gender difference is even more pronounced for large grants (both longer than 4 years in duration and greater than £1 million in value) where women make up 17% of applicants and their success rate is 24% compared with 38% among their male counterparts.<sup>29</sup>

Within the UK, the Equality Challenge Unit set up the Athena SWAN charter in 2005. This scheme aims to tackle gender inequalities in STEMM by awarding bronze, silver or gold awards to universities, research institutions or departments which can demonstrate their commitment to reducing inequalities with measurable performance data. In 2011, the National Institute for Health Research (NIHR) decided that they would only consider application from research groups with at least a Silver Athena SWAN award,<sup>30</sup> thereby further incentivising engagement with this scheme. Recent evidence suggests that there has been an associated positive impact in the advancement of gender equality as reported by participants of the scheme.<sup>31</sup> Furthermore, in the latest call for research professorships, the NIHR guidance has specified a maximum of two nominations per institution at least one of which must be female.<sup>32</sup>

Further to those discussed, there are several additional limitations to our study. We are dependent on the accuracy of the original investment data sourced from the funding bodies. Private sector data was excluded from this study due to incompleteness of publicly available data from this sector. We were not able to include data on applicant success rate, the amount of funding initially requested, the gender co-applicants for each grant, the total gender pool of researchers in each disease area and within each type of science, or the proportion of awards made to clinical and non-clinical researchers, all of which would have provided a more holistic understanding of the research landscape. We lacked data on the academic rankings of PIs and were unable to adjust for seniority across both genders. Unfortunately, CRUK would not




**Figure 1** Proportion of annual UK cancer research funding by gender.

provide disaggregated funding data and so could not be included in our full analysis. However, the proportion of CRUK studies awarded by PI gender was comparable to our reported results (online supplementary appendix 1).

While the gender discrepancies in cancer research funding observed over the 13-year study period are likely multifactorial, this study is fundamentally descriptive in

nature and does not allow us to postulate the underlying mechanisms responsible for the observed gender differences. Nevertheless, this study demonstrates substantial gender imbalances in cancer research investment. We would strongly urge policy-makers, funders and the academic and scientific community to investigate the factors leading to our observed differences and seek to



**Figure 2** Sum total of annual UK cancer research funding by gender.

ensure that women are appropriately supported in scientific endeavour.

#### Author affiliations

<sup>1</sup>Department of Nuclear Medicine, Royal Free NHS Foundation Trust, London, UK

<sup>2</sup>Faculty of Medicine, Institute for Life Sciences, Global Health Research Institute, University of Southampton, Southampton, UK

<sup>3</sup>Oxford University Clinical Academic Graduate School, John Radcliffe Hospital, Oxford, UK

<sup>4</sup>Department of Economics, University of Oxford, Oxford, UK

<sup>5</sup>Faculty of Medicine, Imperial College London, London, UK

<sup>6</sup>Department of Applied Health Research, University College London, London, UK

<sup>7</sup>School of Media, Communication and Sociology, University of Leicester, Leicester, UK

<sup>8</sup>Harvard T. H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA

<sup>9</sup>Department of Epidemiology and Public Health, University College London, London, UK

**Acknowledgements** We would like to thank Joseph Fitchett for his contributions to the Research Investments in Global Health Study.

**Contributors** CDZ, MM, MGH and RA conceived and designed the study. MGH, CDZ, BJG and MAE-H obtained the data. DCM and MGH conducted data formatting and statistical analysis. All authors helped interpret the findings. CDZ wrote the first draft of the manuscript with input from MM, MGH, RR, HO'C and RA. All authors provided input to subsequent drafts. All authors had full access to all of the data in the study and take responsibility for its integrity and the accuracy of data analysis.

**Funding** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** All data used are publicly available. Entire database and associated figures are permanently available with open access online (<http://www.researchinvestments.org>).

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

#### REFERENCES

- European Commission. More women in senior positions - key to economic stability and growth. 2010. <http://www.eubusiness.com/topics/employment/women-senior.10/>
- European Commission. She Figures 2012. Gender in Research and Innovation. Statistics and Indicators. *Econ Soc* 2013;156.
- Burrelli J. *Thirty-Three Years of Women in S&E Faculty Positions*: US National Science Foundation, 2008.
- Pohlhaus JR, Jiang H, Sutton J. Sex differences in career development awardees' subsequent grant attainment. *Ann Intern Med* 2010;152:616.
- Lincoln AE, Pincus SH, Leboy PS. Scholars' awards go mainly to men. *Nature* 2011;469:472.
- UNESCO. UNESCO - Women in Science Visualisation. 2017. <http://uis.unesco.org/apps/visualisations/women-in-science/>
- European Commission. Meta-analysis of gender and science research. 2012;229. [https://ec.europa.eu/research/swafs/pdf/pub\\_gender\\_equality/meta-analysis-of-gender-and-science-research-synthesis-report.pdf](https://ec.europa.eu/research/swafs/pdf/pub_gender_equality/meta-analysis-of-gender-and-science-research-synthesis-report.pdf)
- Science D, Charman-Anderson S, Kane L, *et al*. Championing the Success of Women in Science, Technology, Engineering, Maths, and Medicine. 2017. <https://doi.org/10.6084/m9.figshare.5463502.v1>
- European Commission. Guidance on Gender Equality in Horizon 2020. 2016;14. [http://ec.europa.eu/research/participants/data/ref/h2020/grants\\_manual/hi/gender/h2020-hi-guide-gender\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/gender/h2020-hi-guide-gender_en.pdf)
- Yong E. Edit-a-thon gets women scientists into Wikipedia. *Nature* 2012.
- Donald A. Throw off the cloak of invisibility. *Nature* 2012;490:447.
- Swain F. Science: It's a girl thing. Excuse me while I die inside. SciencePunk. 2012. <http://scienceblogs.com/sciencepunk/2012/06/22/science-its-a-girl-thing-excuse-me-while-i-die-inside/>
- European Commission. She figures 2015. 2016;224. [https://ec.europa.eu/research/swafs/pdf/pub\\_gender\\_equality/she\\_figures\\_2015-final.pdf](https://ec.europa.eu/research/swafs/pdf/pub_gender_equality/she_figures_2015-final.pdf)
- Meulders D, O'Drochai S, Plasman R, *et al*. Gender wage gap and funding. Meta-analysis of gender and science research - Topic report. 2010;135. [https://genderinnovations.stanford.edu/images/TR2\\_Payfunding.pdf](https://genderinnovations.stanford.edu/images/TR2_Payfunding.pdf)
- Pohlhaus JR, Jiang H, Wagner RM, *et al*. Sex differences in application, success, and funding rates for NIH extramural programs. *Acad Med* 2011;86:759-67.
- Bedi G, Van Dam NT, Munafò M. Gender inequality in awarded research grants. *Lancet* 2012;380:474.
- Jagsi R, Motomura AR, Amarnath S, *et al*. Under-representation of women in high-impact published clinical cancer research. *Cancer* 2009;115:3293-301.
- Boyle P, O'Connor H, Holliday L. How should universities and Research Councils proactively respond to gender bias in success rates in grant applications? 2016. [http://www.foundation.org.uk/Events/pdf/20160622\\_Summary.pdf](http://www.foundation.org.uk/Events/pdf/20160622_Summary.pdf)
- Moss-Racusin CA, Dovidio JF, Brescoll VL, *et al*. Science faculty's subtle gender biases favor male students. *Proc Natl Acad Sci U S A* 2012;109:16474-9.
- Boyle PJ, Smith LK, Cooper NJ, *et al*. Gender balance: women are funded more fairly in social science. *Nature* 2015;525:181-3.
- Head MG, Fitchett JR, Cooke MK, *et al*. Differences in research funding for women scientists: a systematic comparison of UK investments in global infectious disease research during 1997-2010. *BMJ Open* 2013;3:e003362.
- Head MG, Fitchett JR, Cooke MK, *et al*. UK investments in global infectious disease research 1997-2010: a case study. *Lancet Infect Dis* 2013;13:55-64.
- Head MG, Fitchett JR, Nageshwaran V, *et al*. Research investments in global health: a systematic analysis of UK infectious disease research funding and global health metrics, 1997-2013. *EBioMedicine* 2016;3:180-90.
- Maruthappu M, Head MG, Zhou CD, *et al*. Investments in cancer research awarded to UK institutions and the global burden of cancer 2000-2013: a systematic analysis. *BMJ Open* 2017;7:e013936.
- Shen H. Inequality quantified: mind the gender gap. *Nature* 2013;495:22-4.
- van der Lee R, Ellemers N. Gender contributes to personal research funding success in The Netherlands. *Proc Natl Acad Sci U S A* 2015;112:12349-53.
- Wennerås C, Wold A. Nepotism and sexism in peer-review. *Nature* 1997;389:326.
- Ceci SJ, Ginther DK, Kahn S, *et al*. Women in academic science: a changing landscape. *Psychol Sci Public Interest* 2014;15:75-141.
- Research Councils UK. Research councils diversity data: trend data on grants awarded and success rates by age and gender. 2016;3. <http://www.rcuk.ac.uk/documents/skills/grantsawardedandsuccessrates-pdf/>
- Medical Schools Council. Athena SWAN. 2017. <https://www.medschools.ac.uk/our-work/equality-inclusivity/athena-swan>
- Osveiko PV, Chapple A, Edmunds LD, *et al*. Advancing gender equality through the Athena SWAN Charter for Women in Science: an exploratory study of women's and men's perceptions. *Health Res Policy Syst* 2017;15:12.
- National Institute for Health Research. NIHR research professorships round 8. 2017. <https://www.nihr.ac.uk/funding-and-support/funding-for-training-and-career-development/training-programmes/nihr-research-professorships/nihr-research-professorships-round-8.htm>